Cancer Biology conferences

This EMBO | EMBL Symposium brings cancer researchers together to examine how tumours spread and resist treatment. Topics include circulating and metastasis-initiating cells, invasion, epigenetic regulation, dormancy, cellular plasticity, immune escape and the tumour microenvironment. The programme connects biological mechanisms with imaging, single-cell and spatial profiling, computational analysis and disease models. The event runs from 10 to 13 November 2026 at the EMBL Advanced Training Centre in Heidelberg, with virtual participation available. Abstract submissions are closed. On-site registration closes on 29 September; virtual registration remains available until 3 November. Registration fees and the two booking routes are listed on the organizer page.

Under the theme Aspiration, Action, Anticipation: AI for Science Looking to 2030, this summit asks how AI is already changing scientific practice and how research may develop over the next few years. Researchers will examine scientific reasoning and discovery alongside applications in cancer biology, climate and weather prediction, animal behaviour and cosmology. Talks, discussion and a poster session connect methodological advances with practical scientific problems. Confirmed contributors include Max Welling, Hana Aliee, Boris Bolliet, Cait Newport, Richard Turner, Neil Lawrence, Stephen Roberts and Sadiq Jaffer. The summit takes place on 24 November, 10:00–18:00, at Churchill College, Cambridge; times are Europe/London, GMT (UTC+00:00). The organizer’s event-specific registration form confirms that online participation is available for remote attendees. In-person places are limited and offered first come, first served, with a waiting list once full. Register using the linked Microsoft Form.

Hosted by the American Society of Hematology, this meeting connects basic and translational blood research with clinical practice. Scientific sessions examine how genomic diagnostics, long-read sequencing and three-dimensional marrow models improve understanding of inherited disorders; how clonal selection and immune escape drive marrow failure; and how RNA regulation offers therapeutic targets in leukemia. AI-assisted flow cytometry, spatial multi-omics and epigenomic profiling link molecular mechanisms to diagnosis and risk stratification. Further sessions investigate stem-cell niches and immune control, tissue-resident T cells, iron homeostasis and erythrocyte metabolism, plasma-cell biology and treatment resistance. Structural and biophysical studies of coagulation, engineered vascular models and targeted imaging address thrombosis and fibrinolysis, including anti-PF4 disorders and safer platelet inhibition. Transplantation and cellular therapies extend into autoimmune disease. Didactic presentations, panels and questions accompany scientific, educational, oral-abstract and poster sessions. Programme times are America/Chicago (CST, UTC−6). The main meeting starts on 12 December with in-person ticketed expert sessions and poster walks at 08:00; Education/Scientific Program and oral-abstract sessions begin at 09:30. The Sunday plenary runs 14:00–16:00, Monday Education/Scientific Program sessions begin at 10:30, and Tuesday late-breaking abstracts begin at 07:30. Best of ASH ends at 13:00 on 15 December. Most sessions stream live; recordings remain available according to the purchased access tier. Friday workshops and satellite symposia are separate pre-meeting activities. Advance in-person or Real-Time virtual fees are USD 900 for active/international members, USD 1,700 for non-members, USD 175 for associate/student/resident members, USD 275 for non-member trainees and USD 800 for allied health professionals. The advance discount ends 21 October at 23:59 Pacific Time; non-member trainee advance rates continue through 1 December. Extended virtual access costs extra. Registration requires an ASH account and payment. In-person expert sessions require separate on-site tickets; trainee-only activities require the appropriate badge.

A conference connecting fundamental cancer research from molecules and cells to tissues, organs and whole organisms. Sessions cover molecular mechanisms, enabling technologies, cell behaviour, and cancer’s interactions with immunity, metabolism and its environment. Early-career and established researchers can develop interdisciplinary collaborations; poster sessions and selected lightning talks provide opportunities to present research. Abstracts close on 30 October 2026, with decisions from 13 November. Early-bird rates ended on 11 September; standard rates apply through 27 November, followed by final admission rates from 28 November. Standard student tickets cost £125, academic/clinical/not-for-profit/healthcare tickets £175 and industry tickets £250; the listed LMIC rate is £50. Programme refreshments and lunches are included.

This Keystone Symposium examines how nerves and neural activity shape cancer initiation, progression, metastasis, cognition, and treatment, with a focus on actionable therapeutic targets.

This symposium compares mechanisms of drug resistance, tolerance and persistence in bacteria, fungi and cancer. It explores how genetic change, non-genetic cellular plasticity, biochemistry and metabolism combine to let cells survive treatment. Themes include evolution under drug pressure, genome plasticity, stress responses, cellular fitness and the ecological context of drug responses. Efflux, microenvironmental effects and other extracellular contributors are considered alongside cellular states and biochemical mechanisms. By comparing systems across species, the programme aims to deepen understanding of clonal evolution and single-cell biology and inform strategies for tackling drug resilience.

The American Association for Cancer Research's flagship annual meeting, themed 'Delivering Discovery Science: The Bridge to Breakthrough Therapeutics', at the Orange County Convention Center in Orlando, Florida.

This conference examines the origins, distribution and consequences of mutations across cells, tissues, organisms and populations. Improved sequencing accuracy, experimental perturbations, multi-omic measurements and computational analysis are brought together to study genetic heterogeneity and its effects on genome function, evolution and disease. Sessions address mechanisms of mutagenesis, technologies for detecting and interpreting mutations, variation across the tree of life, tissue-level diversity, and evolutionary dynamics in cancer and other diseases. Researchers from genomics, mutagenesis, evolution, developmental and functional biology can compare methods and questions across scales that are often studied separately.